Company Aptorum Group Limited

APM

KYG6096M1226

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Annual profits - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 03:59:50 2024-05-23 pm EDT			5-day change	1st Jan Change
4.01 ^USD	-0.99%		-14.68%	+63.77%

Apr. 30	Aptorum Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 06	Top Midday Gainers	MT

Aptorum Group Limited is a United Kingdom-based clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.

Number of employees: 3

USD in Million	2022	Weight	2023	Weight	Delta
Healthcare Service 100.0 %	1	100.0 %	0	100.0 %	-66.71%

USD in Million	2022	Weight	2023	Weight	Delta
Hong Kong 100.0 %	1	100.0 %	0	100.0 %	-66.71%

Managers	Title	Age	Since
Ian Huen FOU	Founder	44	10-09-12
Martin Siu DFI	Director of Finance/CFO	-	22-06-30

Members of the board	Title	Age	Since
Mirko Scherer BRD	Director/Board Member	55	17-09-30
Ian Huen FOU	Founder	44	10-09-12
Justin Wu BRD	Director/Board Member	54	17-09-30
Charles Bathurst BRD	Director/Board Member	69	17-09-30
Douglas Arner BRD	Director/Board Member	54	18-03-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	2,243,776	0	0	53.05 %
Stock B	1	2,937,921	2,749,082 ( 93.57 %)	0

Name	Equities	%	Valuation
Darren Lui 13.67 %	401,537	13.67 %	2 M $
Ian Huen 12.60 %	370,308	12.60 %	2 M $
Geode Capital Management LLC 1.342 %	39,427	1.342 %	216 060 $
Murchinson Ltd. 0.4765 %	14,000	0.4765 %	76 720 $
Morgan Stanley Capital Services LLC 0.1120 %	3,290	0.1120 %	18 029 $
Tower Research Capital LLC 0.0531 %	1,560	0.0531 %	8 549 $
NewEdge Advisors LLC 0.000034 %	1	0.000034 %	5 $
Hudson Bay Capital Management LP 0.000000 %	0	0.000000 %	- $

Name	Equities	%	Valuation
Ian Huen 7.158 %	1,606,147	7.158 %	9 M $

Aptorum Group Ltd.

17 Hanover Square

W1S 1BN, London

+44 20 8092 9299

http://www.aptorumgroup.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
APTORUM GROUP LIMITED	+63.77%	22.16M
ELI LILLY AND COMPANY	+38.69%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.49%	369B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	168B

Other Pharmaceuticals